A randomized phase II trial of MEK and CDK4/6 inhibitors in metastatic KRAS/NRAS mutant CRC showed no substantial improvement compared to the control groups, although MEK and CDK4/6 inhibitors improved the progression-free survival in the subgroup of CRC50. Here, MAP2K7 is linked to colorectal carcinoma.